H. R. 941

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

February 8, 2021

Ms. MATSUI (for herself, Mr. BILIRAKIS, and Ms. PINGREE) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2021” or the “TRANSPLANT Act of 2021”.

VerDate Sep 11 2014 22:20 Mar 05, 2021 Jkt 019200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H941.IH H941kjohnson on DSK79L0C42PROD with BILLS
SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL TRANSPLANTATION PROGRAM.

(a) ADVISORY COUNCIL MEETINGS.—Subsection (a) of section 379 of the Public Health Service Act (42 U.S.C. 274k) is amended by adding at the end the following new paragraph:

“(7) The Secretary shall convene the Advisory Council at least two times each calendar year.”.

(b) INCREASING COLLECTION.—

(1) TECHNICAL CLARIFICATION.—Effective as if included in the enactment of Public Law 114–104 (the Stem Cell Therapeutic and Research Reauthorization Act of 2015), the amendment to section 379(d)(2)(B) of the Public Health Service Act (42 U.S.C. 274k(d)(2)(B)) in section 2(a)(2) of Public Law 114–104 is amended by inserting “goal of increasing collections of high quality” before “cord blood units,”.

(2) ELIMINATING DEADWOOD.—Subparagraph (B) of section 379(d)(2) of the Public Health Service Act (42 U.S.C. 274k(d)(2)) is amended by striking the second and third sentences in such subparagraph.

(c) PERIODIC REVIEW OF STATE OF SCIENCE.—Section 379 of the Public Health Service Act (42 U.S.C.
HR 941 IH

274k) is amended by adding at the end the following new subsection:

“(o) Periodic Review of State of Science.—

“(1) Review.—Not less frequently than every 2 years, the Secretary, in consultation with the Director of the National Institutes of Health, the Commissioner of Food and Drugs, the Administrator of the Health Resources and Services Administration, the Advisory Council, and other stakeholders, where appropriate given relevant expertise, shall conduct a review of the state of the science of using adult stem cells and birthing tissues to develop new types of therapies for patients, for the purpose of considering the potential inclusion of such new types of therapies in the Program.

“(2) Recommendations.—Not later than June 30, 2025, the Secretary shall—

“(A) complete the second review required by paragraph (1); and

“(B) informed by such review, submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Rep-resentatives recommendations on the appro-
priateness of the inclusion of new types of therapies in the Program.”.

(d) Authorization of Appropriations.—Section 379B of the Public Health Service Act (42 U.S.C. 274m) is amended by striking “$33,000,000 for fiscal year 2015 and $30,000,000 for each of fiscal years 2016 through 2020” and inserting “$31,009,000 for each of fiscal years 2022 through 2026”.

SEC. 3. CORD BLOOD INVENTORY.

Subsection (g) of section 2 of the Stem Cell Therapeutic and Research Act of 2005 (42 U.S.C. 274k note) is amended to read as follows:

“(g) Authorization of Appropriations.—To carry out this section, there is authorized to be appropriated $23,000,000 for each of fiscal years 2022 through 2026.”.

SEC. 4. ADVANCING THE FIELD OF REGENERATIVE MEDICINE.

Section 402 of the Public Health Service Act (42 U.S.C. 282) is amended by adding at the end the following:

“(o) Regenerative Medicine.—The Director of NIH shall, as appropriate, continue to consult with the directors of relevant institutes and centers of the National Institutes of Health, other relevant experts from such in-
stitutes and centers, and relevant experts within the Food
and Drug Administration, to further the field of regenera-
tive medicine using adult stem cells, including autologous
stem cells, therapeutic tissue engineering products, human
cell and tissue products, human gene therapies, and ge-
etically modified cells.”.

SEC. 5. GAO REPORT ON REGENERATIVE MEDICINE WORK-
FORCE.

Not later than 2 years after the date of enactment
of this Act, the Comptroller General of the United States
shall submit to the Committee on Health, Education,
Labor, and Pensions of the Senate and the Committee on
Energy and Commerce of the House of Representatives
a report that assesses a specialized health care workforce
in the field of regenerative medicine. The report shall in-
clude—

(1) an overview of the current employment lev-
els, in both commercial and academic settings, for—

(A) positions necessary for the collection
and transplantation of stem cell therapeutics,
including bone marrow and cord blood; and

(B) positions in the field of regenerative
medicine using adult stem cells and related to
product development;
(2) the identification of gaps, if any, in the projected workforce capacity for—

(A) positions described in paragraph (1)(A); and

(B) the field of regenerative medicine using adult stem cells, including workforce gaps related to the development of new cellular therapies using adult stem cells;

(3) an overview of the availability of training programs related to the development, refinement, and utilization of adult stem cells, including training on good manufacturing practices for such activities, and the performance of such programs; and

(4) recommendations, if any, for improving the workforce capacity related to—

(A) the positions described in paragraph (1)(A); or

(B) the field of regenerative medicine using adult stem cells.